{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:15:27Z","timestamp":1761948927892,"version":"3.44.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["20161001610PTJ-378238"],"award-info":[{"award-number":["20161001610PTJ-378238"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol Myers Squibb\u2013Pfizer Alliance"},{"DOI":"10.13039\/501100000222","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000222","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Stroke Prevention Intervention Network"},{"DOI":"10.13039\/100008360","name":"Hamilton Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008360","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Accelerating Clinical Trials Network"},{"DOI":"10.13039\/100030936","name":"Population Health Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030936","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016304","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Apixaban was superior to aspirin for the prevention of stroke or systemic embolism in participants with subclinical atrial fibrillation (SCAF) in the Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation trial. This was especially true for those with CHA2DS2-VASc score &amp;gt; 4. Understanding the cost-effectiveness of treating SCAF is important for decision-makers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Canadian, UK, German, and US direct healthcare costs [in 2023 US dollars (USD)] were applied to hospitalized events (including strokes and bleeds) and study drugs for all participants with a CHA2DS2-VASc score &amp;gt; 4 to determine the mean cost per participant during the trial (mean follow-up 3.5\u2005years). A daily cost of $0.63, $0.11, $2.26, and $6.06 for apixaban in Canada, the UK, Germany, and the USA was used. If in-trial results were not cost-saving (below $0), the prospective plan was to perform a lifetime cost-effectiveness analysis using a Markov model and a willingness-to-pay of 50 000 USD per quality-adjusted life year (QALY). After considering the cost of study medication and clinical events over 3.5\u2005years, apixaban was dominant (cost-saving and more effective) in Canada (\u2212$2301) and the UK (\u2212$902) but cost more in Germany and the USA ($600 and $1990, respectively). Over a lifetime, treatment with apixaban produced a net gain of 0.107 QALYs, but with costs in both Germany ($2623 more) and the USA ($9110 more), yielding an incremental cost-effectiveness ratio of $24 514 per QALY for Germany and $85 140 for the USA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with SCAF and a CHA2DS2-VASc score &amp;gt; 4, apixaban is cost saving in Canada and the UK and cost-effective in Germany. Apixaban was not cost-effective in the USA under the base cost assumption but would be cost-effective at a daily cost of $4.35 and cost saving at $3.59.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euaf195","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:42:42Z","timestamp":1756294962000},"source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-7621","authenticated-orcid":false,"given":"Andre","family":"Lamy","sequence":"first","affiliation":[{"name":"Population Health Research Institute, McMaster University , 237 Barton Street East, Hamilton, Ontario, L8L2X2 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2629-3476","authenticated-orcid":false,"given":"Roopinder K","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Canadian VIGOUR Centre, University of Alberta , Edmonton, AB ,","place":["Canada"]},{"name":"Department of Cardiac Sciences, University of Calgary , Calgary, AB ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2983-6103","authenticated-orcid":false,"given":"Wesley","family":"Tong","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , 237 Barton Street East, Hamilton, Ontario, L8L2X2 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6082-7542","authenticated-orcid":false,"given":"William F","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , 237 Barton Street East, Hamilton, Ontario, L8L2X2 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-4961","authenticated-orcid":false,"given":"Renato D","family":"Lopes","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0045-3291","authenticated-orcid":false,"given":"Christopher B","family":"Granger","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5783-6648","authenticated-orcid":false,"given":"David J","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Liverpool Heart and Chest Hospital , Liverpool ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0631-0010","authenticated-orcid":false,"given":"Jens C","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University , Aarhus ,","place":["Denmark"]},{"name":"Department of Cardiology, Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-289X","authenticated-orcid":false,"given":"Valentina","family":"Kutyifa","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Semmelweis University , Budapest ,","place":["Hungary"]},{"name":"Clinical Cardiovascular Research Center, University of Rochester , Rochester, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3145-6767","authenticated-orcid":false,"given":"Julia W","family":"Erath","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Goethe University, University Hospital , Frankfurt ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-4683","authenticated-orcid":false,"given":"Marco","family":"Alings","sequence":"additional","affiliation":[{"name":"Breda and WCN, Amphia Ziekenhuis , Utrecht ,","place":["Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6495-1428","authenticated-orcid":false,"given":"David H","family":"Birnie","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Ottawa Heart Institute , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-8793","authenticated-orcid":false,"given":"Dan","family":"Atar","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ulleval , Oslo ,","place":["Norway"]},{"name":"Institute of Clinical Medicine, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5030-3315","authenticated-orcid":false,"given":"Stefan H","family":"Hohnloser","sequence":"additional","affiliation":[{"name":"Department of Cardiology, J.W. Goethe University , Frankfurt am Main ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9039-6023","authenticated-orcid":false,"given":"Cecilia","family":"Linde","sequence":"additional","affiliation":[{"name":"Heart, Vascular and Neurology Theme, Karolinska University Hospital, Stockholm ,","place":["Sweden"]},{"name":"Department of Cardiology, Karolinska Institutet, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1632-6182","authenticated-orcid":false,"given":"Josef","family":"Kautzner","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Institute for Clinical and Experimental Medicine (IKEM) , Praha 4 ,","place":["Czech Republic"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3912-8901","authenticated-orcid":false,"given":"Juan","family":"Benezet-Mazuecos","sequence":"additional","affiliation":[{"name":"Arrhytmia Unit, Hospital Universitario La Luz , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-2871","authenticated-orcid":false,"given":"A John","family":"Camm","sequence":"additional","affiliation":[{"name":"Cardiology Clinical Academic Group Molecular & Clinical Sciences Institute, City St George's University of London , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8428-7050","authenticated-orcid":false,"given":"Christian","family":"Sticherling","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Basel , Basel ,","place":["Switzerland"]},{"name":"Department of Cardiology, Cardiovascular Research Institute Basel , Basel ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4579-0216","authenticated-orcid":false,"given":"Michael R","family":"Gold","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina , Charleston, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte E","family":"Larroud\u00e9","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev-Gentofte Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-7580","authenticated-orcid":false,"given":"Jeff S","family":"Healey","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University , 237 Barton Street East, Hamilton, Ontario, L8L2X2 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"2025091920133680700_euaf195-B1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"2025091920133680700_euaf195-B2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"2025091920133680700_euaf195-B3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"Subclinical atrial fibrillation and the risk of stroke","volume":"366","author":"Healey","year":"2012","journal-title":"N Engl J Med"},{"key":"2025091920133680700_euaf195-B4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation","volume":"390","author":"Healey","year":"2024","journal-title":"N Engl J Med"},{"key":"2025091920133680700_euaf195-B5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jacc.2024.05.002","article-title":"Apixaban vs aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: insights from ARTESiA","volume":"84","author":"Lopes","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025091920133680700_euaf195-B6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1474-4422(24)00475-7","article-title":"Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial","volume":"24","author":"Shoamanesh","year":"2025","journal-title":"Lancet Neurol"},{"key":"2025091920133680700_euaf195-B7","doi-asserted-by":"crossref","DOI":"10.1016\/j.hrthm.2025.07.002","article-title":"Atrial fibrillation progression in patients with device-detected subclinical atrial fibrillation: insights from the ARTESiA trial","author":"Boriani","year":"2025","journal-title":"Heart Rhythm"},{"key":"2025091920133680700_euaf195-B8","doi-asserted-by":"crossref","first-page":"102651","DOI":"10.1016\/j.eclinm.2024.102651","article-title":"Cost effectiveness analysis of a fixed dose combination pill for primary prevention of cardiovascular disease from an individual participant data meta-analysis","volume":"73","author":"Lamy","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2025091920133680700_euaf195-B9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/ehjqcco\/qcac054","article-title":"The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial","volume":"9","author":"Lamy","year":"2023","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"author":"Medicinal forms | Apixaban | Drugs | BNF | NICE","key":"2025091920133680700_euaf195-B10"},{"author":"NHS England","key":"2025091920133680700_euaf195-B11"},{"key":"2025091920133680700_euaf195-B12","first-page":"782","article-title":"The effectiveness and value of rivaroxaban and icosapent ethyl as additive therapies for cardiovascular disease","volume":"26","author":"Synnott","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"author":"Medicare Inpatient Hospitals\u2014by Geography and Service | CMS Data","key":"2025091920133680700_euaf195-B13"},{"key":"2025091920133680700_euaf195-B14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1017\/S0317167100015638","article-title":"Impact of disability status on ischemic stroke costs in Canada in the first year","volume":"39","author":"Mittmann","year":"2012","journal-title":"Can J Neurol Sci"},{"key":"2025091920133680700_euaf195-B15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13244-021-01077-4","article-title":"Cost-effectiveness of artificial intelligence aided vessel occlusion detection in acute stroke: an early health technology assessment","volume":"12","author":"van Leeuwen","year":"2021","journal-title":"Insights Imaging"},{"key":"2025091920133680700_euaf195-B16","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.jval.2021.05.005","article-title":"Cost-effectiveness of magnetic resonance imaging-guided thrombolysis for patients with stroke with unknown time of onset","volume":"24","author":"Muntendorf","year":"2021","journal-title":"Value Health"},{"key":"2025091920133680700_euaf195-B17","doi-asserted-by":"crossref","first-page":"e004513","DOI":"10.1161\/JAHA.116.004513","article-title":"Observed cost and variations in short term cost-effectiveness of therapy for ischemic stroke in interventional management of stroke (IMS) III","volume":"6","author":"Simpson","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2025091920133680700_euaf195-B18","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euae031","article-title":"Economic analyses in cardiac electrophysiology: from clinical efficacy to cost utility","volume":"26","author":"Frausing","year":"2024","journal-title":"Europace"},{"key":"2025091920133680700_euaf195-B19","first-page":"1","article-title":"United States life tables, 2021","volume":"72","author":"Arias","year":"2023","journal-title":"Natl Vital Stat Rep"},{"key":"2025091920133680700_euaf195-B20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/2396987316683780","article-title":"Dependency and health utilities in stroke: data to inform cost-effectiveness analyses","volume":"2","author":"Ali","year":"2017","journal-title":"Eur Stroke J"},{"key":"2025091920133680700_euaf195-B21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000452634","article-title":"Comparison of 3-month stroke disability and quality of life across modified Rankin scale categories","volume":"6","author":"Rangaraju","year":"2017","journal-title":"Interv Neurol"},{"key":"2025091920133680700_euaf195-B22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12955-015-0344-z","article-title":"Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients","volume":"13","author":"Kiadaliri","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"2025091920133680700_euaf195-B23","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40258-023-00815-7","article-title":"10 years of AMNOG: what is the willingness-to-pay for pharmaceuticals in Germany?","volume":"21","author":"B\u00fcssgen","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"key":"2025091920133680700_euaf195-B24","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","article-title":"Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures","volume":"11","author":"Pichon-Riviere","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2025091920133680700_euaf195-B25","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2025091920133680700_euaf195-B26","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"2025091920133680700_euaf195-B27","doi-asserted-by":"crossref","first-page":"euad226","DOI":"10.1093\/europace\/euad226","article-title":"Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal","volume":"25","author":"Lip","year":"2023","journal-title":"Europace"},{"key":"2025091920133680700_euaf195-B28","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euad166","article-title":"The influence of atrial high-rate episodes on stroke and cardiovascular death: an update","volume":"25","author":"Toennis","year":"2023","journal-title":"Europace"},{"key":"2025091920133680700_euaf195-B29","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1093\/eurheartj\/ehae596","article-title":"Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials","volume":"45","author":"Schnabel","year":"2024","journal-title":"Eur Heart J"},{"key":"2025091920133680700_euaf195-B30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.7326\/0003-4819-155-9-201111010-00004","article-title":"Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable","volume":"155","author":"Connolly","year":"2011","journal-title":"Ann Intern Med"},{"key":"2025091920133680700_euaf195-B31","first-page":"465","article-title":"Evaluation of patients\u2019 attitudes towards stroke prevention and bleeding risk in atrial fibrillation","volume":"111","author":"Lahaye","year":"2014","journal-title":"Thromb Haemost"},{"key":"2025091920133680700_euaf195-B32","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/bmj.323.7323.1218","article-title":"Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study","volume":"323","author":"Devereaux","year":"2001","journal-title":"BMJ"},{"key":"2025091920133680700_euaf195-B33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2024.06.022","article-title":"Performance of HAS-BLED and DOAC scores to predict major bleeding events in atrial fibrillation patients treated with direct oral anticoagulants: a report from a prospective European observational registry","volume":"128","author":"Mei","year":"2024","journal-title":"Eur J Intern Med"},{"author":"Frothingham","key":"2025091920133680700_euaf195-B34"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/advance-article-pdf\/doi\/10.1093\/europace\/euaf195\/64165044\/euaf195.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/27\/9\/euaf195\/64165044\/euaf195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/27\/9\/euaf195\/64165044\/euaf195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:13:49Z","timestamp":1758327229000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euaf195\/8244471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euaf195","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"type":"print","value":"1099-5129"},{"type":"electronic","value":"1532-2092"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,31]]},"article-number":"euaf195"}}